Opin vísindi

Anti–Citrullinated Protein Antibody Specificities, Rheumatoid Factor Isotypes, and Incident Cardiovascular Events in Patients With Rheumatoid Arthritis

Skoða venjulega færslu

dc.contributor Háskóli Íslands
dc.contributor University of Iceland
dc.contributor.author Westerlind, Helga
dc.contributor.author Rönnelid, Johan
dc.contributor.author Hansson, Monika
dc.contributor.author Alfredsson, Lars
dc.contributor.author Mathsson‐Alm, Linda
dc.contributor.author Serre, Guy
dc.contributor.author Cornillet, Martin
dc.contributor.author Holmdahl, Rikard
dc.contributor.author Jakobsson, Per‐Johan
dc.contributor.author Skriner, Karl
dc.contributor.author Klareskog, Lars
dc.contributor.author Saevarsdottir, Saedis
dc.contributor.author Askling, Johan
dc.date.accessioned 2020-11-06T16:04:53Z
dc.date.available 2020-11-06T16:04:53Z
dc.date.issued 2020-09-07
dc.identifier.citation Westerlind, H., Rönnelid, J., Hansson, M., Alfredsson, L., Mathsson‐Alm, L., Serre, G., Cornillet, M., Holmdahl, R., Jakobsson, P.‐J., Skriner, K., Klareskog, L., Saevarsdottir, S. and Askling, J. (2020), Anti–Citrullinated Protein Antibody Specificities, Rheumatoid Factor Isotypes, and Incident Cardiovascular Events in Patients With Rheumatoid Arthritis. Arthritis Rheumatol, 72: 1658-1667. doi:10.1002/art.41381
dc.identifier.issn 2326-5191
dc.identifier.issn 2326-5205 (eISSN)
dc.identifier.uri https://hdl.handle.net/20.500.11815/2179
dc.description Publisher's version (útgefin grein)
dc.description.abstract Objective: To investigate the relationship between anti–citrullinated protein antibodies (ACPAs), specific ACPA subspecificities, rheumatoid factor (RF) isotypes, and incident cardiovascular (CV) events in patients with rheumatoid arthritis (RA). Methods: Serum samples from Swedish patients with new-onset RA (diagnosed within 1 year of symptom onset between 1996 and 2009) were centrally typed for anti–cyclic citrullinated peptide 2 (anti-CCP2) antibodies, 20 ACPA subspecificities, and RF isotypes. Patients were followed up longitudinally in nationwide registers to monitor the occurrence of acute coronary syndrome (ACS), stroke, CV-related death, and major adverse CV events (MACE). The association between each serologic marker and CV outcome, and the impact of adjustment for the Disease Activity Score in 28 joints (DAS28), smoking status, and income at baseline, were assessed using Cox proportional hazards models. In addition, associations of serologic markers with all-cause mortality were explored. Results: In total, 2,814 patients with RA were included in the study. The median follow-up was 13 years, during which the CV end points of ACS, stroke, or CV-related death were reported to occur in 375 patients. Occurrence and/or levels of anti-CCP2 were associated with risk of incident ACS (hazard ratio [HR] 1.46, 95% confidence interval [95% CI] 1.03–2.06), stroke (HR 1.47, 95% CI 1.03–2.10), CV-related death (P = 0.024 for association with anti-CCP2 levels), and MACE (HR 1.34, 95% CI 1.06–1.70). Similarly, an association with the number of ACPA subspecificities was observed; however, this could not be attributed to any individual or group of ACPA subspecificities. Presence of IgM-RF was associated with all CV end points except ACS, and IgA-RF was exclusively associated with CV-related death. Adjustment for smoking status, income, and DAS28 scores decreased most of the HRs, whereas IgA-RF remained associated with CV-related death (HR 1.61, 95% CI 1.05–2.48). All of the assessed serologic makers were associated with all-cause mortality. Conclusion: RF isotypes and ACPAs are associated with future CV events in patients with RA. ACPA levels and number of subspecificities seem more important than the occurrence of particular subspecificities, and these associations were not explained by a history of ever smoking.
dc.description.sponsorship Karolinska institutet (strategic research area epidemiology), The nordic research council (nordforsk), The rheumatology research foundation (foreum), Stiftelsen för Strategisk Forskning, Vetenskapsrådet, Stockholms Läns Landsting, The swedish heart lung foundation
dc.format.extent 1658-1667
dc.language.iso en
dc.publisher Wiley
dc.relation.ispartofseries Arthritis & Rheumatology;72(10)
dc.rights info:eu-repo/semantics/openAccess
dc.subject Rheumatoid arthritis
dc.subject Cardiovascular disease
dc.subject Iktsýki
dc.subject Kransæðasjúkdómar
dc.title Anti–Citrullinated Protein Antibody Specificities, Rheumatoid Factor Isotypes, and Incident Cardiovascular Events in Patients With Rheumatoid Arthritis
dc.type info:eu-repo/semantics/article
dcterms.license This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
dc.description.version Peer Reviewed
dc.identifier.journal Arthritis & Rheumatology
dc.identifier.doi 10.1002/art.41381
dc.relation.url https://onlinelibrary.wiley.com/doi/10.1002/art.41381
dc.contributor.department Læknadeild (HÍ)
dc.contributor.department Faculty of Medicine (UI)
dc.contributor.school Heilbrigðisvísindasvið (HÍ)
dc.contributor.school School of Health Sciences (UI)


Skrár

Þetta verk birtist í eftirfarandi safni/söfnum:

Skoða venjulega færslu